Drug Hits Target in Advanced Biliary Cancer

(MedPage Today) -- A fourth of previously treated cholangiocarcinomas (CCA) responded to a tyrosine kinase inhibitor (TKI) targeting the fibroblast growth factor receptor (FGFR) family, a phase II open-label study showed.
Confirmed objective responses...